bioRxiv Science⌕ Search

bioRxiv · 10.1101/2022.06.14.496046

A spatial statistical framework for the parametric study of fiber networks: application to fibronectin deposition by normal and activated fibroblasts

Abstract

Changes in the spatial landscape of the extracellular matrix (ECM) in health and disease significantly impact the surrounding tissues. Quantifying the spatial variations in the fibrillar architecture of major ECM proteins could enable a profound understanding of the link between tissue structure and function. We propose a method to capture relevant ECM features using graph networks for fiber representation in normal and tumor-like states of 4 alternatively spliced isoforms of fibronectin (FN) associated with embryonic development and disease. Then, we construct graph-derived statistical parametric maps, to study the differences across variants in normal and tumor-like architectures. This novel statistical analysis approach, inspired from the analysis of functional magnetic resonance imaging (fMRI) images, provides an appropriate framework for measuring and detecting local variations of meaningful matrix parameters. We show that parametric maps representing fiber length and pore orientation isotropy can be studied within the proposed framework to differentiate among various tissue states. Such tools can potentially lead to a better understanding of dynamic matrix networks within the tumor microenvironment and contribute to the development of better imaging modalities for monitoring their remodeling and normalization following therapeutic intervention. Author SummaryDue to the complex architectural diversity of biological networks, there is an increasing need to complement statistical analyses with a qualitative and local description. The extracellular matrix (ECM) is one such network for which fiber arrangement has a major impact on tissue structure and function. Thus, a flexible numerical representation of fibrillar networks is needed for accurate analysis and meaningful statistical comparison of ECM in healthy and diseased tissue. First, we propose a versatile computational pipeline to study fiber-specific features of the ECM with graph networks. Then, we introduce a novel framework for the statistical analysis of graph-derived parametric maps, inspired from the statistical analysis of fMRI parametric maps. This analysis is useful for the quantitative/qualitative comparison of ECM fiber networks observed in normal and tumor-like, or fibrotic states. These methods are applied to study networks of fibronectin (FN), a provisional ECM component that dictates the organization of matrix structure. From 2D confocal images we analyzed architectural variations among 4 alternatively spliced isoforms of FN, termed oncofetal FN, that are prevalent in diseased tissue. We show how our approach can be used for the computation and statistical comparison of heterogeneous parametric maps representing FN variant-specific topological/geometrical features. These methods may be further developed and implemented into tumor tissue ECM profiling to decipher the specific roles of ECM landscapes and their remodeling in disease.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Grapa, A.-I., Efthymiou, G., Van Obberghen-Schilling, E., Blanc-Feraud, L., Descombes, X.. 2022-06-16. A spatial statistical framework for the parametric study of fiber networks: application to fibronectin deposition by normal and activated fibroblasts. https://doi.org/10.1101/2022.06.14.496046

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

The Phospholipase A2 Activity of Peroxiredoxin 6 Protects Hepatocarcinoma Cells Against Ferroptosis and Mitophagy Impairment

Peroxiredoxin 6 (PRDX6) is a moonlighting protein that plays a key role in regulating redox homeostasis and lipid metabolism through its unique dual peroxidase and calcium-independent phospholipase A2 (iPLA2) activities. Here, we generated a stable HepG2 cell line harboring a D140A mutation to selectively ablate iPLA2 activity, and we compared its phenotype with that of wild-type (WT) and PRDX6-knockout (KO) cells. D140A exhibited low ROS leves, similar to WT cells, confirming that oxidative stress is due to peroxidase deficiency. In contrast, D140A cells displayed higher lipid peroxidation than WT cells, though significantly lower than that of KO cells. Furthermore, the D140A mutant mirrored the KO phenotype regarding intracellular ferrous iron accumulation, impaired lipid droplet biogenesis, and the downregulation of the key ferroptosis regulator GPX4. Mechanistically, integrated proteomic, lipidomic, and enzymatic analyses revealed that a deficiency in iPLA2 activity of PRDX6 disrupted the release of key lipid species necessary for cell structure and signaling. Consequently, organelles involved in lipid synthesis and trafficking, such as peroxisomes, endoplasmic reticulum, mitochondria and lipid droplet, were affected. Specifically, we found that mitochondria exhibited a reduction in cristae and a diminished capacity for mitophagy and autophagy, which ultimately makes cells much more susceptible to erastin-induced ferroptotic cell death. Taken together, our findings demonstrate that PRDX6 iPLA2 activity uniquely coordinates organelle lipid homeostasis and mitophagy to protect cancer cells from ferroptotic cell death. Consequently, the use of iPLA2 inhibitors such as MJ33, which decreased PRDX6 iPLA2 activity to a level comparable to the mutant D140A, could represent a promising therapeutic strategy for inducing ferroptotic cell death in hepatocellular carcinoma.

cancer biology↗

Serum extracellular vesicle proteomics reveals treatment-associated biomarkers in pancreatic ductal adenocarcinoma

Background Longitudinal biomarkers of treatment response in pancreatic ductal adenocarcinoma (PDAC) are needed. Extracellular vesicle (EV)-enriched serum proteomics may provide a minimally invasive approach for monitoring systemic and tumor-associated responses to therapy. Methods Paired pre-treatment and post-treatment serum samples were analyzed from 51 patients with pancreatic cancer, including 25 treated with FOLFIRINOX and 20 treated with gemcitabine-based therapy. EVs were enriched using the Mag-Net method and profiled by data independent acquisition mass spectrometry. After batch correction and filtering, 941 proteins were retained for differential and pathway analyses. Paired linear models and gene set enrichment analyses were used to assess treatment-associated changes. Baseline protein abundance and longitudinal changes were evaluated in relation to overall survival (OS) using Cox models. Results A total of 2,089 EV-associated proteins were identified, with an average of 1,186 proteins quantified per sample. Across the cohort, 26 proteins differed between post- and pretreatment samples. Proteins that increased after treatment were primarily related to extracellular matrix organization and cell adhesion, whereas proteins that decreased after treatment were associated with actin cytoskeletal organization, coagulation, and hemostasis. Treatment-associated changes were more pronounced in the FOLFIRINOX group, in which 32 proteins were differentially expressed. FOLFIRINOX was characterized by coordinated reductions in platelet- and coagulation-associated proteins, including PF4, PF4V1, PPBP, GP5, ITGA2B, and ITGB3, accompanied by enrichment of platelet activation, coagulation, and hemostasis pathways among down-regulated processes. No individual proteins met the same significance threshold in the gemcitabine group. A composite seven-protein platelet score decreased significantly after FOLFIRINOX but not for gemcitabine, and the between-regimen difference in score change was significant. Higher pretreatment ITGB1 abundance was associated with longer OS after multiple-testing correction (HR, 0.112; BH-FDR = 0.0063). In multivariable analysis, greater treatment-associated platelet-score depletion was independently associated with shorter OS (HR per unit increase in {Delta}score, 0.56; P = 0.030). Conclusions Longitudinal serum EV-enriched proteomics identified treatment-associated biological changes in PDAC, including a coordinated platelet-related response predominantly observed after FOLFIRINOX. Baseline ITGB1 abundance and longitudinal platelet-score changes represent potentially complementary prognostic and pharmacodynamic markers. These findings are exploratory and require validation in larger, independent cohorts incorporating platelet counts, coagulation measurements, and targeted proteomic assays.

cancer biology↗

BAF complexes cooperate with lineage-restricted transcription factors to establish cell-state-specific regulatory programs

BRG1/BRM-associated factor (BAF) complexes are essential regulators of chromatin organization and cell identity. Genes encoding BAF subunits are among the most frequently mutated in human cancer. Yet, how disruption of a single subunit gives rise to distinct tumor states remains poorly understood. Atypical teratoid rhabdoid tumors (ATRTs) provide a compelling model, as they are uniformly driven by bi-allelic loss of the BAF subunit SMARCB1, yet segregate into distinct molecular subtypes. Using integrated multi-omics profiling of patient-derived ATRT organoids and primary tumor tissues, we show that transcriptional and chromatin accessibility changes upon SMARCB1 reconstitution are directed by subtype- and lineage-specific transcription factor (TF) repertoires. Genome-wide binding and transcriptomic analyses reveal that SMARCB1 reconstitution enables the lineage-specific TF RFX4 to engage regulatory elements and activate neuronal differentiation programs, partially reprogramming ATRT-MYC toward an ATRT-SHH-like identity. Together, these findings demonstrate that SMARCB1 loss disrupts TF-dependent chromatin priming, revealing that the lineage-specific regulatory output of BAF complexes is constrained by the underlying TF repertoire.

cancer biology↗